A clinical study for patients with moderate to severe Alzheimer's disease using Memantine hydrochloride OD tablet.

A clinical study for patients with moderate to severe Alzheimer's disease using Memantine hydrochloride OD tablet. - A clinical study for patients with moderate to severe Alzheimer's disease using Memantine hydrochloride OD tablet.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014581

Enrollment

Registered

2014-07-22

Start date

2014-08-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer&#39

Interventions

Switching from Memantine hydrochloride tablet 20mg to Memantine hydrochloride OD tablet 20mg Intervention period of 4 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients who are diagnosed as moderate to severe Alzheimer's disease by investigator 2.Patients who have taken Memantine hydrochloride tablet 20mg for 4 weeks before evaluation period 3.Patients who are 20 years or over 4.Patients who are able to understand this study and give informed consent in literature by patient and a caregiver or families

Exclusion criteria

Exclusion criteria: 1.Dementia patients except Alzheimer's disease 2.Patients who have severe mental disorder 3.Patients who are pregnant or trying to get pregnant, or during breastfeeding 4.Patients with a history of the hypersensitivity for Memantine hydrochloride tablets 5.The case that a investigator judged to be inappropriate

Design outcomes

Primary

Measure	Time frame
Evaluation of functionality	—

Secondary

Measure	Time frame
Evaluation of safety	—

Countries

Japan

Contacts

Public ContactHiroki Kato

Sogo Rinsho Medefi Company Limited Business Promotion Department

kato.hiroki@sogo-medefi.jp03-6901-6079

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

A clinical study for patients with moderate to severe Alzheimer&#39;s disease using Memantine hydrochloride OD tablet.